AtaiBeckley Inc. (ATAI)
| Market Cap | 1.55B |
| Revenue (ttm) | 4.09M |
| Net Income (ttm) | -660.05M |
| Shares Out | 364.75M |
| EPS (ttm) | -2.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,326,776 |
| Open | 4.290 |
| Previous Close | 4.340 |
| Day's Range | 4.225 - 4.500 |
| 52-Week Range | 1.290 - 6.750 |
| Beta | 1.57 |
| Analysts | Strong Buy |
| Price Target | 15.88 (+273.21%) |
| Earnings Date | May 11, 2026 |
About ATAI
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophr... [Read more]
Financial Performance
In 2025, AtaiBeckley's revenue was $4.09 million, an increase of 1227.60% compared to the previous year's $308,000. Losses were -$660.05 million, 342.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price target is $15.88, which is an increase of 273.21% from the latest price.
News
AtaiBeckley Transcript: Needham Virtual Psychedelics Forum
Psychedelic drug development is accelerating due to regulatory support and robust clinical data, with companies preparing for earlier approvals and focusing on scalable, durable treatments. Market adoption will depend on efficacy, payer engagement, and operational models, with infrastructure and reimbursement pathways rapidly evolving.
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track Order
ATAI surged 28.1% in premarket trading as investors piled into the sector after the administration's weekend directive. The move sparked a broad wave of buying across psychedelic‑focused companies.
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference
Late-stage clinical programs focus on short-duration psychedelic therapies for mental health, with BPL-003 entering phase III for TRD and promising phase II data showing rapid, durable effects. Market strategy targets integration into existing Spravato clinics, and top-line phase III results are expected in Q1 2029.
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics ...
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response
The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market pr...
AtaiBeckley Transcript: Leerink Global Healthcare Conference 2026
Three advanced assets for mental health—BPL-003, VLS-01, and EMP-01—show strong efficacy and short treatment durations, aligning with the SPRAVATO clinic model. Regulatory-aligned trials and robust infrastructure position these therapies for broad adoption in interventional psychiatry.
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Transcript: Investor Day 2026
BPL-003, a next-generation, short-acting psychedelic for TRD, is advancing into phase III trials after strong phase IIb results, with a focus on rapid, durable, and convenient treatment. The commercial model leverages existing infrastructure, supports premium pricing, and is backed by robust IP. Clinicians and experts anticipate broad adoption if efficacy and safety are confirmed.
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by deve...
AtaiBeckley Transcript: TD Cowen 46th Annual Health Care Conference
Two pivotal Phase III trials for BPL-003 in TRD are underway, featuring single and double dosing regimens with placebo controls and enhanced safety monitoring. Phase IIb data support the 8 mg dose for efficacy and tolerability. EMP-01 in social anxiety disorder showed rapid, SSRI-comparable behavioral improvements, with further analyses expected soon.
AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data
AtaiBeckley Inc. (NASDAQ: ATAI) on Thursday shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.
AtaiBeckley Transcript: Study result
EMP-01, an oral R-MDMA, showed promising safety and efficacy in a phase IIa trial for severe social anxiety disorder, with rapid and clinically meaningful improvements in both fear and avoidance after two doses. The compound was well tolerated, with a unique psychedelic profile and no severe adverse events. Further analyses and dose-ranging studies are planned.
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile EMP-01 demonstrated a clinically meaningful placebo-adju...
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developin...
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developin...
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by develo...